Richter-Helm Biologics and INOVIO will expand existing DNA manufacturing agreement to support large-scale manufacturing of Inovio’s investigational DNA vaccine for COVID-19

Richter-Helm Biologics, Gedeon Richter Plc. (“Richter”) and Helm AG’s joint venture microbial biotechnology contract development and cGMP manufacturing organization, today announced it has entered into an agreement with US based INOVIO (NASDAQ: INO) to expand its manufacturing partnership in order to support large-scale manufacturing of INOVIO’s investigational DNA vaccine for COVID-19, INO-4800, which is currently in Phase 1 clinical testing in the U.S. and and could potentially advance to Phase 2/3 efficacy trials this summer.

​INOVIO has been working with Richter-Helm BioLogics since 2014. INOVIO has established commercial-scale plasmid production at Richter-Helm BioLogics for its DNA medicines platform using the manufacturing technology developed by VGXI, Inc with successful technology transfer already demonstrated in previous projects.

INOVIO has assembled a global coalition of collaborators, partners and funders to rapidly advance INO-4800.

“This agreement continues to strengthen Richter-Helm Biologics’ position as an experienced and reliable contract development and manufacturing organization in microbially produced biologics. The agreement is also an example of Richter’s continued commitment to strengthen the Group’s capabilities in the field of biopharmaceuticals”

said Dr Erik Bogsch, Deputy Director of Biotechnology Business Unit, Head of R&D and Manufacturing.
Share on twitter
Share on email

More News

Richter entered into an asset purchase agreement with Mycenax for the biosimilar tocilizumab

Richter entered into an asset purchase agreement with Mycenax for the biosimilar tocilizumab

Gedeon Richter Plc. (“Richter”) today announced that it has entered into an asset purchase agreement…
Richter launched Terrosa, its biosimilar teriparatide across Europe

Richter launched Terrosa, its biosimilar teriparatide across Europe

Gedeon Richter Plc. (“Richter”) today announced that it has launched its biosimilar teriparatide, Terrosa® in…